Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 0.0% | 0.0% | 30.1% | 33.7% | 46.0% | 16.1% | 9.8% | 2.3% | 11.6% |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Microsoft Corp's last 12-month Return on Equity (ROE) is 4.9%, based on the financial report for Sep 30, 2024 (Q3 2024). The average annual Return on Equity (ROE) for Royalty Pharma plc have been 8.8% over the past three years, and 13.1% over the past five years.
As of today, Royalty Pharma plc's Return on Equity (ROE) is 4.9%, which is higher than industry median of (52.7%). It indicates that Royalty Pharma plc's Return on Equity (ROE) is Good.